본문 바로가기

A Therapeutic Strategy for Chemotherapy-Resistant Gastric Cancer via Destabilization of Both beta-Cateninand RAS

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q2
저널
CANCERS11(4) · 2019
피인용
Web of Science 12Scopus 13
FWCI (Scopus)
0.49
JCR IF
JCR 2018 6.162
ISSN
2072-6694

저자

  1. Ryu, Won-Ji제1저자Translational Research Center for Protein Function Control, Yonsei University, Seoul, 03722, Korea
  2. Lee, Jae EunDepartment of Surgery, Yonsei University College of Medicine, Seoul, 03722, Korea
  3. Cho, Yong-HeeTranslational Research Center for Protein Function Control, Yonsei University, Seoul, 03722, Korea
  4. Lee, GunhoDepartment of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, 03722, Korea
  5. Seo, Mi-KyoungDepartment of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, 03722, Korea
  6. Lee, Sang-KyuTranslational Research Center for Protein Function Control, Yonsei University, Seoul, 03722, Korea
  7. Hwang, Jeong-HaTranslational Research Center for Protein Function Control, Yonsei University, Seoul, 03722, Korea
  8. 민도식Department of Molecular Biology, College of Natural Science, Pusan National University, Pusan, 46241, Korea
  9. Noh, Sung HoonDepartment of Surgery, Yonsei University College of Medicine, Seoul, 03722, Korea
  10. Paik, SoonmyungSeverance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, 03722, Korea
  11. Kim, SangwooDepartment of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, 03722, Korea
  12. Cheong, Jae-Ho교신저자Department of Surgery, Yonsei University College of Medicine, Seoul, 03722, Korea
  13. Choi, Kang-Yell교신저자Translational Research Center for Protein Function Control, Yonsei University, Seoul, 03722, Korea

초록

Treatment of advanced gastric cancer patients with current standard chemotherapeutic agents frequently results in resistance, leading to poor overall survival. However, there has been no success in developing strategies to overcome it. We showed the expression levels of both beta-catenin and RAS were significantly increased and correlated in tissues of 756 gastric cancer (GC) patients and tissues of primary- and acquired-resistance patient-derived xenograft tumors treated with 5-fluorouracil and oxaliplatin modulated with leucovorin (FOLFOX). On the basis of our previous studies, where small molecules to suppress colorectal cancer (CRC) via degrading both beta-catenin and RAS were developed, we tested the effectiveness of KYA1797K, a representative compound functioning by binding axin, in the growth of GC cells. The efficacy test of the drugs using gastric tumor organoids of Apc(1638N) mice showed that the CD44 and ALDH1A3 cancer stem cell markers were induced by FOLFOX, but not by KYA1797K. KYA1797K also efficiently suppressed tumors generated by re-engrafting the FOLFOX-resistant patient-derived xenograft (PDX) tumors, which also showed resistance to paclitaxel. Overall, the small-molecule approach degrading both beta-catenin and RAS has potential as a therapeutic strategy for treating GC patients resistant to current standard chemotherapies.

키워드

gastric cancerchemotherapy resistancedegradation of both beta-catenin and RASgastric cancer patient-derived xenograftHELICOBACTER-PYLORI INFECTIONGENEAPCLOCALIZATIONINSTABILITYEXPRESSIONMUTATIONPATHWAYCOLON

식별자

Scopus EID
2-s2.0-85065388958
WoS UID
000467773400064